Evogene Reports Q2 2025 Financial Results: Revenue Up 39%, Operating Expenses Down 31%

Evogene reported H1 2025 revenues of $3.2 million, up 39% YoY, driven by increased seed sales from its subsidiary, Casterra. The company reduced operating expenses by 31% to $7.7 million and achieved a net loss reduction of $2.1 million. The strategic sale of Lavie Bio and MicroBoost AI for $18.71 million strengthened its financial position. Evogene's focus on its ChemPass AI platform aims to unlock value in the pharmaceutical and agricultural markets.